This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Divine Skin Posts Q3 Revenue Of $2.1 Million, Up 35% From 2010

MIAMI BEACH, Fla., Nov. 15, 2011 /PRNewswire/ -- Biotechnology leader Divine Skin Inc., (OTC Bulletin Board: DSKX) which develops personal care products, posted revenue of $2.1 million for the third quarter, up 35 percent from 2010. The rapidly expanding company reported nine-month revenue of $6.6 million, up 74 percent from last year.

"We are on track for another record-breaking year," said Divine Skin CEO Daniel Khesin. "These days, there are so many opportunities to commercialize new scientific discoveries, and we are taking full advantage. We couldn't be in a better position right now."

The positive results came after a busy quarter of big announcements.

In July: Divine Skin expanded into the lucrative market for supplements by partnering with NutraOrigin, developer of 63 blends of nutritional formulas; and the company launched a global partnership with India's huge Ranbaxy Laboratories to sell its DS Laboratories line of hair-growth treatments worldwide.

In August: Divine Skin debuted a new molecule, Nanoxidil, designed to stimulate follicles at the vertex of the scalp, eventually to surpass minoxidil for efficacy and tolerability; and it entered into new distribution agreements for South Korea, Canada, Australia, Taiwan, South Africa, Belgium, and Finland.

In September: Divine Skin launched the market's first topical treatment to incorporate astressin-B, a complex peptide newly discovered to regrow hair on bald mice. The company also became the first to synthesize the peptide for human use in a cosmetic product, marketed as Spectral.F7 under the DS Laboratories brand.

About Divine Skin

Divine Skin Inc. leads in the development of biotechnology for topical, nutritional, and pharmaceutical therapies. It markets worldwide through online and specialty retailers, cosmetics wholesalers, salons, and medical offices. The fast-growing company went public in 2009.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,185.07 -103.56 -0.57%
S&P 500 2,105.08 -12.31 -0.58%
NASDAQ 4,971.2270 -36.8690 -0.74%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs